Recombinant Human IL-36 beta/IL-1F8 (aa 5-157) Protein, CF

Recombinant Human IL-36 beta/IL-1F8 (Catalog #6834-ILB/CF) induces IL-8 secretion in A431 human epithelial carcinoma cells. The ED50 for this effect is 0.8-4.8 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-36 beta/IL-1F8 (aa 5-157) Protein, CF Summary

• Details of Functionality: Measured by its ability to induce IL-8 secretion in A431 human epithelial carcinoma cells. The ED₅₀ for this effect is 0.8-4.8 ng/mL.
• Source: E. coli-derived human IL-36 beta/IL-1F8 protein
  Arg5-Glu157
• Accession #: NP_775270
• N-terminal Sequence: Arg5
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL36B
• Purity: >95%, by SDS-PAGE with silver staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 17 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 17 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE with silver staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-36 beta/IL-1F8 (aa 5-157) Protein, CF

• family of interleukin 1-eta
• FIL1 eta
• FIL1
• FIL1-(ETA)
• FIL1H
• FILI-(ETA)
• IL-1 eta
• IL1-ETA
• IL1F8 (Canonical product IL-1F8a)
• IL-1F8 (FIL1-eta)
• IL1F8
• IL-1F8
• IL1H2
• IL-1H2
• IL36 beta
• IL-36 beta
• IL36B
• interleukin 1 family, member 8 (eta)
• interleukin 1, eta
• Interleukin 36, Beta
• Interleukin-1 eta
• interleukin-1 family member 8
• Interleukin-1 homolog 2
• Interleukin-1 Superfamily e
• Interleukin-36 Beta

Background

Interleukin-36 beta (IL-36 beta , previously known as IL-1F8, FIL-1 eta (eta) and IL-1H2, is a member of the IL-1 family of proteins that also includes IL-1 beta , IL-1 alpha , IL-1ra,
IL-18, IL-36Ra/IL-1F5, IL-36 alpha /IL-1F6, IL-37/IL-1F7, IL-36 gamma /IL-1F9, and IL-1F10 (1, 2). IL-1 family cytokines are characterized by a 12  beta -stranded beta -trefoil configuration and share up to 50% amino acid (aa) sequence identity. The 157 aa human IL-36 beta does not have a canonical signal peptide or prosegment and is expressed as two isoforms that differ in their C-terminal 70 aa. IL-36 beta 1 lacks four of the conserved beta -strands common to the IL-1 family (3). Human IL-36 beta 2 shares 62%, 67%, 63% and 59% aa identity with the most similar isoforms of mouse, canine, bovine and equine IL-36 beta , respectively (4). IL-36 beta is expressed by keratinocytes, naïve CD4⁺ T cells, neurons, and glia (5-7). It is up-regulated in keratinocytes and synovial fibroblasts by inflammatory stimulation and in psoriatic lesions (5, 8, 9). IL-36 beta promotes inflammatory responses by enhancing the activation and Th1 polarization of dendritic cells and T cells (7, 10, 11). It also enhances the production of multiple pro-inflammatory cytokines, chemokines, and anti-bacterial defensin peptides by keratinocytes, synovial fibroblasts, and articular chondrocytes (5, 8-10). IL-36 proteins exert their bioactivity through a receptor complex that contains IL-1 Rrp2 and IL-1 RAcP, and this is antagonized by IL-36Ra which also binds IL-1 Rrp2 (11, 12). The potency of IL-36 beta is increased by cleavage of its first four N-terminal amino acids (13).

1. Garlanda, C. et al. (2013) Immunity 39:1003.
2. Gresnigt, M.S. and F.L. van de Veerdonk (2013) Semin. Immunol. 25:458.
3. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
4. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
5. Johnston, A. et al. (2011) J. Immunol. 186:2613.
6. Wang, P. et al. (2005) Cytokine 29:245.
7. Vigne, S. et al. (2012) Blood 120:3478.
8. Magne, D. et al. (2005) Arthritis Res. Ther. 8:R80.
9. Carrier, Y. et al. (2011) J. Invest. Dermatol. 131:2428.
10. Foster, A.M. et al. (2014) J. Immunol. 192:6053.
11. Vigne, S. et al. (2011) Blood 118:5813.
12. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
13. Towne, J.E. et al. (2011) J. Biol. Chem. 286:42594.

Publications for IL-36 beta/IL-1F8 (6834-ILB/CF)(3)

Publications using 6834-ILB/CF

• WR Swindell, MA Beamer, MK Sarkar, S Loftus, J Fullmer, X Xing, NL Ward, LC Tsoi, MJ Kahlenberg, Y Liang, JE Gudjonsson RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature Front Immunol, 2018-01-29;9(0):80. 2018-01-29 [PMID: 29434599] (Cell Culture, Human)
• Guanghui Yi Structural and functional attributes of the Interleukin-36 receptor J Biol Chem, 2016-06-15;0(0):. 2016-06-15 [PMID: 27307043] (Bioassay, Human)
• Saha S, Singh D, Raymond E, Ganesan R, Caviness G, Grimaldi C, Woska J, Mennerich D, Brown S, Mbow M, Kao C Signal Transduction and Intracellular Trafficking by the Interleukin 36 Receptor. J Biol Chem, 2015-08-12;290(39):23997-4006. 2015-08-12 [PMID: 26269592] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IL36B
• Uniprot:
  • NP_775270()